English
Specials
    Upgrade
    MoneycontrolBe a PRO
    Moneycontrol PRO

    business

    Dishman Pharma eyes 15% topline, bottomline growth in FY12

    In an interview with CNBC-TV18, VVS Murthy, CFO, Dishman Pharma said the company is expecting 15% top-line and bottom-line growth in FY12.

    first published: Jun 13, 2011 03:30 pm

    LATEST VIDEOS

    Watch More →

    A collection of the most-viewed Moneycontrol videos.

    Watch and Follow our leading shows